ASPSCR1: A Potential Drug Target and Biomarker for SLC2A4-UBX Transcript Variants

Target Name: ASPSCR1

NCBI ID: G79058

ASPSCR1

ASPSCR1: A Potential Drug Target and Biomarker for SLC2A4-UBX Transcript Variants

Introduction

Sodium channel subfamily A (SLC2A4) is a gene that encodes a protein known as SLC2A4, which is a key component of the sodium channel. This gene has four variants, ASPSCR1, ASPSCR2, ASPSCR3, and ASPSCR4, which result in different protein sizes and functions. The most abundant variant is ASPSCR1, which is also the most well-studied variant. This gene has been implicated in various neurological and cardiovascular diseases, including epilepsy, bipolar disorder, and heart failure.

Recent studies have suggested that ASPSCR1 may be a drug target and a biomarker for certain diseases. In this article, we will explore the potential drug targets and biomarkers associated with ASPSCR1 and its variants.

Drug Targets

ASPSCR1 has been identified as a potential drug target for several diseases. Its function in the sodium channel has been implicated in the pathophysiology of several conditions, including epilepsy, bipolar disorder, and heart failure.

1. Epilepsy: ASPSCR1 has been shown to be overexpressed in epilepsy patients. Elevated ASPSCR1 levels have been associated with an increased risk of epileptic episodes and a poor response to traditional epilepsy treatments.

2. Bipolar Disorder: ASPSCR1 has been implicated in the pathophysiology of bipolar disorder. Studies have shown that individuals with the ASPSCR1 variant are more likely to develop bipolar disorder than those without the variant.

3. Heart Failure: ASPSCR1 has been associated with heart failure. Studies have shown that individuals with the ASPSCR1 variant have an increased risk of developing heart failure compared to those without the variant.

Biomarkers

ASPSCR1 has also been identified as a potential biomarker for several diseases. Its function in the sodium channel has been implicated in the pathophysiology of several conditions, including epilepsy, bipolar disorder, and heart failure.

1. Epilepsy: ASPSCR1 has been shown to be overexpressed in individuals with epilepsy. Elevated ASPSCR1 levels have been associated with an increased risk of epileptic episodes and a poor response to traditional epilepsy treatments.

2. Bipolar Disorder: ASPSCR1 has been implicated in the pathophysiology of bipolar disorder. Studies have shown that individuals with the ASPSCR1 variant are more likely to develop bipolar disorder than those without the variant.

3. Heart Failure: ASPSCR1 has been associated with heart failure. Studies have shown that individuals with the ASPSCR1 variant have an increased risk of developing heart failure compared to those without the variant.

Conclusion

In conclusion, ASPSCR1 is a gene that has been implicated in various neurological and cardiovascular diseases. Its function in the sodium channel has been associated with the pathophysiology of several conditions, including epilepsy, bipolar disorder, and heart failure. Recently, studies have suggested that ASPSCR1 may be a drug target and a biomarker for these diseases. Further research is needed to confirm these findings and to explore the potential clinical applications of ASPSCR1 and its variants.

Protein Name: ASPSCR1 Tether For SLC2A4, UBX Domain Containing

Functions: Tethering protein that sequesters GLUT4-containing vesicles in the cytoplasm in the absence of insulin. Modulates the amount of GLUT4 that is available at the cell surface (By similarity). Enhances VCP methylation catalyzed by VCPKMT

The "ASPSCR1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ASPSCR1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets